Compared with the CHF model group, the ANP level in the captopril and SFAS-H groups was significantly decreased (P < 0.05; Figure 8A), and BNP and NE levels in all treatment groups significantly decreased (P < 0.05, P < 0.01, or P < 0.001; Figures 8B,C). Here, NPPA is linked to congestive heart failure.